Online inquiry

IVTScrip™ mRNA-Anti-CD19, SGN-19A(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14738MR)

This product GTTS-WQ14738MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD19 gene. The antibody can be applied in B cell acute lymphoblastic leukemia (B cell ALL), Refractory B-lineage non-Hodgkin lymphoma research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001178098.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 930
UniProt ID P15391
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19, SGN-19A(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ14738MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4188MR IVTScrip™ mRNA-Anti-IL2RA, BIIB019(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BIIB019
GTTS-WQ13894MR IVTScrip™ mRNA-Anti-PDGFRB, REGN-2176(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-2176
GTTS-WQ9589MR IVTScrip™ mRNA-Anti-VSIR, JNJ-61610588(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA JNJ-61610588
GTTS-WQ3073MR IVTScrip™ mRNA-Anti-TFPI, Anti-TFPI(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA Anti-TFPI
GTTS-WQ4521MR IVTScrip™ mRNA-Anti-CXCL10, BMS-936557(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BMS-936557
GTTS-WQ13163MR IVTScrip™ mRNA-Anti-TNFRSF4, PF-04518600(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA PF-04518600
GTTS-WQ11204MR IVTScrip™ mRNA-Anti-TNFRSF18, MEDI-1873(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MEDI-1873
GTTS-WQ13746MR IVTScrip™ mRNA-Anti-ANGPTL3, REGN 1500(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA REGN 1500
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW